Compared side by side
HGH vs IGF-1 LR3: how they differ
The short answer
HGH is recombinant growth hormone, which stimulates IGF-1, the growth factor the liver and muscles make when GH arrives and the messenger that does much of GH’s building work. IGF-1 LR3 is a lab-modified copy of IGF-1 built to slip past the proteins that normally hold IGF-1 in reserve, which makes it more potent in a dish and in rats. HGH is FDA-approved for GH deficiency and several growth disorders; IGF-1 LR3 has no human studies, and low blood sugar is the one documented risk of its class.
Side by side
| Compared | HGH | IGF-1 LR3 |
|---|---|---|
| Category | Growth hormone | Growth hormone |
| Also known as | GH, rHGH, Human Growth Hormone, Growth Hormone, Somatropin, hGH | Long R3 IGF-1, LR3 IGF-1, LongR3-IGF-I, Long [Arg3] IGF-I, IGF1 LR3, IGF-1 Long R3 |
| What it is | Recombinant human growth hormone — an identical copy of the GH your pituitary makes. | IGF-1 is the growth factor your liver and muscles make when growth hormone arrives — the messenger that does much of GH's building work. |
| How it works | Recombinant human growth hormone. Binds GH receptors to stimulate IGF-1 production, protein synthesis, and lipolysis. Promotes muscle growth, fat oxidation, and tissue repair. Structurally identical to pituitary GH, though injections don't reproduce its natural pulses. | A laboratory-built version of IGF-1: human IGF-1 with glutamate at position 3 swapped for arginine and an 11-amino-acid tail from pig growth hormone added to the front. Both changes do one thing — they make it bind the IGF-binding proteins about a thousand times more weakly, so it circulates free and reaches the IGF-1 receptor instead of being held in reserve. That is where its extra potency comes from, not from a stronger signal: in cells that make no binding proteins it is weaker than IGF-1. In rats it grew body weight, gut and organs; in pigs the same infusion did the opposite and suppressed their own GH, insulin and IGF-1. No human study of it has been published. |
| Commonly reported | Water retention, numb or tingling fingers, joint aches, and better sleep and skin. Requires careful dosing and IGF-1 monitoring — more is not always better. | Fuller muscles and quicker recovery, hunger, and the shaky, sweaty, light-headed feeling of a blood-sugar dip within an hour or two of a dose. There are no human studies of it, and low blood sugar is the one documented risk of the class. |
| Studied range | Research range: 1–4 IU. Studied in research — not a recommendation. | Research range: 20–50 mcg, starting dose 20 mcg. Studied in research — not a recommendation. |
| How often | Daily SubQ injection. | Daily (community protocols: training days) |
| Half-life | ~3-4 hours (SubQ) | Not measured in people: no human pharmacokinetic study of IGF-1 LR3 has been published. In rats it cleared from plasma about ten times faster than IGF-1 (Bastian 1993), because escaping the binding proteins is both what makes it potent and what lets it clear. The 20–30 hour figure repeated across community guides traces to one unreferenced sentence in the methods of a mouse atherosclerosis paper and has never been measured. |
| Route | SubQ injection | SubQ injection |
| Typical run | Commonly reported starting dose 1-2 IU daily. Advanced users may run 3-4 IU split AM/PM. Cycles of 3-6+ months common. Monitor IGF-1 levels. Also run alongside peptide stacks; some advanced protocols add insulin, which isn't in this library. | Community cycles commonly run 3 to 6 weeks with an equal or longer break, on the belief that the IGF-1 receptor downregulates; no study has tested that in people. The animal work that found it anabolic used continuous infusion from an implanted pump over 7 to 14 days; given as daily injections it worked much less well than by infusion, though it still beat plain IGF-1 on several measures (not on muscle loss in catabolic rats). |
| Evidence | Established: clinical trials or FDA-approved use exists | Emerging: primarily preclinical / limited human data |
| Common side effects | Water retention, joint pain, carpal tunnel syndrome, morning fatigue, injection site reactions | Low blood sugar symptoms (shakiness, sweating, light-headedness), hunger, injection site reaction, water retention, joint ache |
- Category
- HGHGrowth hormone
- IGF-1 LR3Growth hormone
- Also known as
- HGHGH, rHGH, Human Growth Hormone, Growth Hormone, Somatropin, hGH
- IGF-1 LR3Long R3 IGF-1, LR3 IGF-1, LongR3-IGF-I, Long [Arg3] IGF-I, IGF1 LR3, IGF-1 Long R3
- What it is
- HGHRecombinant human growth hormone — an identical copy of the GH your pituitary makes.
- IGF-1 LR3IGF-1 is the growth factor your liver and muscles make when growth hormone arrives — the messenger that does much of GH's building work.
- How it works
- HGHRecombinant human growth hormone. Binds GH receptors to stimulate IGF-1 production, protein synthesis, and lipolysis. Promotes muscle growth, fat oxidation, and tissue repair. Structurally identical to pituitary GH, though injections don't reproduce its natural pulses.
- IGF-1 LR3A laboratory-built version of IGF-1: human IGF-1 with glutamate at position 3 swapped for arginine and an 11-amino-acid tail from pig growth hormone added to the front. Both changes do one thing — they make it bind the IGF-binding proteins about a thousand times more weakly, so it circulates free and reaches the IGF-1 receptor instead of being held in reserve. That is where its extra potency comes from, not from a stronger signal: in cells that make no binding proteins it is weaker than IGF-1. In rats it grew body weight, gut and organs; in pigs the same infusion did the opposite and suppressed their own GH, insulin and IGF-1. No human study of it has been published.
- Commonly reported
- HGHWater retention, numb or tingling fingers, joint aches, and better sleep and skin. Requires careful dosing and IGF-1 monitoring — more is not always better.
- IGF-1 LR3Fuller muscles and quicker recovery, hunger, and the shaky, sweaty, light-headed feeling of a blood-sugar dip within an hour or two of a dose. There are no human studies of it, and low blood sugar is the one documented risk of the class.
- Studied range
- HGHResearch range: 1–4 IU. Studied in research — not a recommendation.
- IGF-1 LR3Research range: 20–50 mcg, starting dose 20 mcg. Studied in research — not a recommendation.
- How often
- HGHDaily SubQ injection.
- IGF-1 LR3Daily (community protocols: training days)
- Half-life
- HGH~3-4 hours (SubQ)
- IGF-1 LR3Not measured in people: no human pharmacokinetic study of IGF-1 LR3 has been published. In rats it cleared from plasma about ten times faster than IGF-1 (Bastian 1993), because escaping the binding proteins is both what makes it potent and what lets it clear. The 20–30 hour figure repeated across community guides traces to one unreferenced sentence in the methods of a mouse atherosclerosis paper and has never been measured.
- Route
- HGHSubQ injection
- IGF-1 LR3SubQ injection
- Typical run
- HGHCommonly reported starting dose 1-2 IU daily. Advanced users may run 3-4 IU split AM/PM. Cycles of 3-6+ months common. Monitor IGF-1 levels. Also run alongside peptide stacks; some advanced protocols add insulin, which isn't in this library.
- IGF-1 LR3Community cycles commonly run 3 to 6 weeks with an equal or longer break, on the belief that the IGF-1 receptor downregulates; no study has tested that in people. The animal work that found it anabolic used continuous infusion from an implanted pump over 7 to 14 days; given as daily injections it worked much less well than by infusion, though it still beat plain IGF-1 on several measures (not on muscle loss in catabolic rats).
- Evidence
- HGHEstablished: clinical trials or FDA-approved use exists
- IGF-1 LR3Emerging: primarily preclinical / limited human data
- Common side effects
- HGHWater retention, joint pain, carpal tunnel syndrome, morning fatigue, injection site reactions
- IGF-1 LR3Low blood sugar symptoms (shakiness, sweating, light-headedness), hunger, injection site reaction, water retention, joint ache
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
HGH
Week-by-week cards for HGH are not in our library.
IGF-1 LR3
- Day 1–14 Low blood sugar is the thing to know first
- Day 1–21 What people notice in the first weeks
- Day 14–42 What the animal studies actually showed
- Day 21–56 The 20–30 hour half-life is not a measurement
- Day 42+ Past six weeks: nothing is mapped
Together or one or the other
HGH and IGF-1 LR3 are a common stack: IGF-1 LR3 lists HGH among its common stacks.
Community · IGF-1 LR3
Stacked on the GH axis: the same arm twice
The common pairing is GH or a secretagogue plus IGF-1 LR3, because one raises your own IGF-1 and the other adds more. Worth seeing clearly: both land on the same receptor pathway, and the side effects that stack are the glucose ones — GH pushes blood sugar up and insulin sensitivity down, while IGF-1 pulls sugar down, so the swings get wider, not smaller.
Questions people ask
How long do HGH and IGF-1 LR3 last?
The half-life of HGH is ~3-4 hours (SubQ). The half-life of IGF-1 LR3 is not measured in people: no human pharmacokinetic study of IGF-1 LR3 has been published. In rats it cleared from plasma about ten times faster than IGF-1 (Bastian 1993), because escaping the binding proteins is both what makes it potent and what lets it clear. The 20–30 hour figure repeated across community guides traces to one unreferenced sentence in the methods of a mouse atherosclerosis paper and has never been measured.
How often are HGH and IGF-1 LR3 taken?
HGH: daily SubQ injection. Route: SubQ injection. IGF-1 LR3: daily (community protocols: training days). Route: SubQ injection.
How are HGH and IGF-1 LR3 dosed in research?
The research range for HGH is 1–4 IU. The research range for IGF-1 LR3 is 20–50 mcg, with a 20 mcg starting dose. Studied in research — not a recommendation.
What are the common side effects of HGH and IGF-1 LR3?
For HGH, the library lists: water retention, joint pain, carpal tunnel syndrome, morning fatigue, injection site reactions. For IGF-1 LR3: low blood sugar symptoms (shakiness, sweating, light-headedness), hunger, injection site reaction, water retention, joint ache.
Are HGH and IGF-1 LR3 taken together?
HGH and IGF-1 LR3 are a common stack: IGF-1 LR3 lists HGH among its common stacks. The common pairing is GH or a secretagogue plus IGF-1 LR3, because one raises your own IGF-1 and the other adds more. Worth seeing clearly: both land on the same receptor pathway, and the side effects that stack are the glucose ones — GH pushes blood sugar up and insulin sensitivity down, while IGF-1 pulls sugar down, so the swings get wider, not smaller.